https://fightcolorectalcancer.org/fight/treatment/

New Post Public Reply Private Reply Replies (1) Message Board
trding trding #5878
619
https://fightcolorectalcancer.org/fight/treat...ent-stage/

Treatments by stage

STAGE 0 AND STAGE I COLON CANCER
Patients diagnosed with stage 0 and stage I colon cancer are often cured by the surgery that removes the cancerous polyps or tumor.

STAGE 0 (IN SITU) COLON CANCER
Surgery is often the recommended treatment for stage 0 colon cancer.

Polypectomy — snaring and removing polyps containing cancer during a colonoscopy
Local excision — removal of flat colon growths “piecemeal” during colonoscopy
Open abdominal surgery — remove cancer, part of colon, and nearby lymph nodes in high risk situations

STAGE I COLON CANCER
For stage I colon cancer, surgery is also often the recommended treatment. It will typically be either:

Colectomy (resection) — removal of all or part of your colon through one incision
Laparoscopic colectomy — when a surgeon makes a few small incisions in your abdomen through which they pass a tiny camera and tools to access your colon
Medically reviewed by Dr. Al Benson, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, 9/23/13

STAGE I RECTAL CANCER
There are a variety of different surgeries used to treat stage I rectal cancer:

Local excision through the anus
Low anterior resection (LAR) for tumors that are high enough in the rectum to permit reconnecting the colon or rectum to the anus (anastomosis)
Abdominoperineal resection with permanent colostomy when the distance between tumor and anus is too short to allow safe anastomosis
Possible Chemotherapy
If the tumor has gone through the outer layer of the rectum (T3) or there are cancer cells in lymph nodes (N1 or N2), then follow-up chemotherapy and chemoradiation may be recommended.

Possible Watch and Wait
For some stage I rectal cancers, there may be the option to watch and wait.

STAGE II COLON CANCER
Initial treatment for stage II colon cancer is surgery to remove the section of colon that contains the tumor and surrounding tissue with its blood vessels and lymph nodes. It could be either:

Open colectomy — when a surgeon makes a long incision in your abdomen so that they can access your colon
Laparoscopic colectomy — when a surgeon makes a few small incisions in your abdomen through which they pass a tiny camera and tools to access your colon
Chemotherapy
Treatment of node-negative stage II colon cancer is controversial. While surgery to remove the tumor in the colon is universally accepted as an initial treatment, the value of chemotherapy after that surgery (adjuvant chemotherapy) to keep cancer from recurring (coming back) is hard for patients and doctors to judge.

It’s estimated that between 4-5 percent of patients with stage II colon cancer will benefit from chemotherapy. However, there are side effects, some severe, associated with chemotherapy.

Clinical Trials
There are often clinical trials available for stage II colon cancer patients.

Medically reviewed by Dr. Al Benson, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, 9/23/13

STAGE II RECTAL CANCER
For patients who are medically fit and able to undergo combined methods of therapy, treatment for stage II and III rectal cancer may consist of:

Chemoradiation before surgery
Abdominal surgery
Adjuvant chemotherapy
Patients with medical issues that make chemoradiation difficult may go directly to surgery, followed by:

No further treatment if their tumor hasn’t spread through the rectal wall or to lymph nodes
A reconsideration of adjuvant chemotherapy and chemoradiation if there is spread through the wall (T3) or into lymph nodes (N1 or N2)

STAGE III COLON CANCER
Most stage III colon cancer patients will receive a recommendation of surgery, colostomy, chemotherapy and possibly radiation.

Combination Chemotherapy
Patients who are able to tolerate combination chemotherapy that includes Eloxatin® are often prescribed:

Folfox — combination treatment with infusional 5-FU (fluorouracil), leucovorin, and oxaliplatin
Flox — combination with bolus 5-FU, leucovorin, and oxaliplatin. Severe diarrhea is more common with Flox than Folfox but outcomes are similar.
(“Bolus dose” is the administration of a medication that is given to raise its concentration in the blood to an effective level.)

Alternative Chemotherapy
Patients who have medical reasons not to use combination chemotherapy may be prescribed:

Xeloda® (capecitabine) — oral “prodrug” which is converted to 5-FU in the tissues
5-FU and leucovorin
Your doctor can discuss the advantages and disadvantages of the different chemotherapy regimens for your individual needs.

Radiation
If surgery reveals the tumor has spread outside the colon, follow-up radiation may be recommended. Radiation is not routine for stage III colon cancer.

Clinical Trials
There are often clinical trials available for stage III colon cancer.

STAGE III RECTAL CANCER
Most stage III rectal cancer patients will receive a recommendation of surgery, chemotherapy and chemoradiation combinations.

Surgery
For rectal cancer, abdominal surgery is often required to remove tumors. You may be treated with radiation and/or chemotherapy before surgery.

Low Anterior Resection (LAR)
Abdominoperineal Resection (APR)
Chemotherapy Combinations
For stage III rectal cancer patients who are medically fit and can tolerate combined methods of therapy, treatment can consist of chemoradiation (chemotherapy and radiation) before surgery (adjuvant therapy), abdominal surgery, and/or adjuvant chemotherapy after surgery.

Patients who cannot tolerate chemoradiation at first, may go directly to surgery with no additional treatment, and then onto adjuvant chemotherapy and/or chemoradiation after surgery.

For a list of chemoradiation options, adjuvant chemotherapy options, and adjuvant chemotherapy options (a “sandwich” of chemo-chemoradiation-chemo), download Your Guide in the Fight.

STAGE IV, METASTATIC CANCER OR RECURRENT CRC
Treatment for stage IV or recurrent colorectal cancer is complex, and generally requires consultation with medical, surgical and radiological doctors. For a list of questions to ask if you have stage IV or recurrent CRC, and for examples of treatment options combined to treat metastatic disease over time, download Your Guide in the Fight.

Take time to get the best information and advice possible from a multidisciplinary team. This process is vitally important. Make sure to get a second opinion, even if it takes extra time.

Surgery
If the liver, lungs, or the lining of the abdomen (peritoneum) are affected, you may undergo multiple surgeries to remove metastatic disease. Often, chemotherapy and radiation are combined with surgery to shrink tumors.

Partial Hepatectomy — also known as a liver resection, this surgery is intended to remove tumors from the liver
Pulmonary Metastasectomy — a surgery where tumors which have metastasized to the lung are removed
Chemoembolization Surgery — sometimes called transarterial chemoembolization (TACE), it is a combination of an embolization procedure (a procedure that reduces blood flow to the liver) and chemotherapy
Hyperthermic Intraperitoneal Chemotherapy — also called HIPEC, this surgery involves filling the abdominal cavity with heated chemotherapy drugs
Chemotherapy Combinations
There are a variety of chemotherapy combinations that may be prescribed.

Capox or Xelox — Capecitabine (Xeloda®) plus oxaliplatin (Eloxatin®). Capecitabine is an oral drug that works the same way as 5-FU inside the cancer cell.
Folfox — 5-FU, Oxaliplatin (Eloxatin®), and Leucovorin
Folfiri — 5-FU, Irinotecan (Camptosar®), and Leucovorin
These regimens may be combined with targeted therapies such as bevacizumab (Avastin®), cetuximab (Erbitux®), or panitumumab (Vectibix®).

Patients who are not able to tolerate intensive therapy have other options. Doctors may recommend:

5-FU plus leucovorin with or without bevacizumab (Avastin®)
Capecitabine (Xeloda®) with or without bevacizumab (Avastin®)
Treatment with capectiabine (Xeloda®) alone should only be considered a reasonable option for selected patients who are not candidates for more aggressive combination regimens with oxaliplatin (Eloxatin®) or irinotecan (Camptosar®).

Other Options
Patients who have stopped responding to other treatments or who cannot receive certain chemotherapy medicines have other options, like trifluridine and tipiracil (Lonsurf®), a nucleoside-analogue drug.

Targeted Therapies
There are approved targeted therapies for colorectal cancer, including:

Cetuximab (Erbitux®)
Panitumumab (Vectibix®)
Bevacizumab (Avastin®)
Ziv-aflibercept (Zaltrap®)
Regorafenib (Stivarga®)
Ramucirumab (Cyramza®)
Vemurafenib (Zelboraf ®)
Immunotherapies
Immunotherapy uses certain parts of a person’s immune system to fight disease. Immunotherapy for colorectal cancer has been shown to be effective in a small subset of patients with a certain biomarker, microsatellite-instability (MSI) or mismatch repair deficiency (MMR). All colorectal patients should know their MSI/MMR status!

Pembrolizumab (Keytruda ®)
This is an option for patients who have the microsatellite instable-high (MSI-H) or deficient mismatch repair (d-MMR) biomarkers. This treatment is indicated for adult and pediatric patients with unresectable or metastatic solid tumors that have been identified as having a MSI-H or dMMR biomarker, including patients with solid tumors that have progressed following prior treatment and who have no alternative treatment options.

Nivolumab (Opdivo ®)
This therapy is for use in microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC). Nivolumab has been approved for mCRC patients whose cancer either progressed after being treated with a fluoropyrimidine, oxaliplatin, and irinotecan, or did not respond to those treatments.

Ipilimumab (Yervoy®)
This drug may be used in combination with nivolumab as a treatment option for metastatic colorectal cancer (mCRC) with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer following the progression on a fluoropyrimidine, oxaliplatin, and irinotecan.

Colorectal cancer treatment by stage can be straightforward in the early stages, but it can become incredibly complicated once the cancer progresses. Our Guide in the Fight includes more detailed colorectal cancer treatment by stage for stage III, IV and recurrent cancers.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Jacob Walthour to Be Honored for Economic Leadership

Updated Category News Views 5

The Honoring of Leadership That Goes Beyond Business In a world where financial influence often feels like it funnels into the same familiar pockets, the news of Jacob Walthour Jr.'s upcoming recognition feels like a fresh breeze of change. The Alpha Phi Alpha's Alpha Alpha Lambda Chapter is rolling out the red carpet at its Centennial Gala for Walthour, throwing him into...

Continue Reading
Ransoms and Mega-Losses Surge in Cyber Claims Study

Updated Category News Views 4

Cyber Costs Skyrocket in Latest Study NetDiligence’s 2026 Cyber Claims Study isn't just another report—it’s a wake-up call. The numbers paint a stark picture: cyber incidents are burning deeper holes in pockets, and no one's immune. Whether you're a scrappy SME or a lumbering corporate giant, this report puts a magnifying glass to the chilling reality of cyber...

Continue Reading
B2B Growth Hinges on Narrative Coherence, Study Shows

Updated Category News Views 5

Clear Stories, Stronger Growth If companies can't tell a clear story that their buyers understand and believe, they're destined to stagnate. That's the blunt reality kompeld is pushing with their H2 2026 Narrative Coherence Benchmark. The report scores 150 B2B tech companies on their narrative coherence, showing there's a stark correlation between storytelling and growth....

Continue Reading
2026 CEE Awards Highlight Energy Innovation Leaders

Updated Category News Views 6

Showcasing Cutting-Edge Home Energy Innovations It's that time of year again when the brightest innovators in home energy solutions get a nod from the Consortium for Energy Efficiency (CEE). This year's Integrated Home Competition spotlighted five trailblazing products that promise to reshape how we think about energy efficiency, demand flexibility, and sheer user comfort...

Continue Reading
NY Sheriffs' Court Battle: Immigration Policies Under Fire

Updated Category News Views 10

Sheriffs Clash with State Over Immigration Policies In a tense showdown reminiscent of an old-time standoff, 15 New York county sheriffs have drawn their battle lines against the state’s capricious maneuvers by pushing a federal court to hit the brakes on Albany’s newly minted immigration rule. The so-called “Local Cops, Local Crimes Act” is catching serious heat,...

Continue Reading
Paula's Choice Elevates Skincare Game with New Campaign

Updated Category News Views 9

Strategy Meets Skincare: Paula's Choice in the Spotlight Catch this: Paula's Choice just dropped a moisturizer, but it ain't just lotion. No, the Pro-Collagen Peptide Plumping Intensive Moisturizer is here with a punch. And they've got Hannah Waddingham, of 'Ted Lasso' fame, fronting a campaign that screams confidence. Now, that's a way to announce your move at the...

Continue Reading
Red Banyan Earns Top Honors in Florida for 2026

Updated Category News Views 5

Red Banyan: A Powerhouse in Reputation Management Boy, have you ever watched a company rise through the ranks almost like a caffeine kick on a drowsy morning? That's Red Banyan for you. This outfit, right out of Fort Lauderdale, snagged the '2026 Best of Florida' award as the cream of the crop in the Business Consulting Firms category. It’s like taking home an Oscar in...

Continue Reading
NOAA Taps ICEYE US for Game-Changing SAR Satellite Data

Updated Category News Views 8

The Strategic Move to SAR Data Imagine this: You’re in the thick of a hurricane, where visibility goes out the window, and traditional satellite data chokes under the crushing weight of clouds and nightfall. That's the precise chaos ICEYE US is cutting through with its Synthetic Aperture Radar (SAR) technology. The latest scuttlebutt is that NOAA's getting cozy with...

Continue Reading
Koogler's Sale to ALL4: A Game-Changer for the Southeast

Updated Category News Views 5

A Strategic Alignment Unfolds in Environmental Engineering Ever notice how those industry shifts often sneak up on you, only to leave a mark that's hard to ignore? That's exactly what's playing out with Koogler & Associates' recent hookup with ALL4 LLC. Set aside that coffee, this one's too important to miss if you've got a stake in the environmental consulting game or...

Continue Reading
TGI Fridays Unveils New 3 For All Menu Options

Updated Category News Views 10

Hedging Bets on New Dining Strategies Oh, the restaurant battlefield—where one day you're the toast of the town, and the next, you're hustling to keep those seats filled. TGI Fridays, a name as synonymous with casual eats as long as I’ve been in this game, is rolling the dice with a new offering dubbed '3 For All.' Doesn't sound like your average meal deal either....

Continue Reading

Top 5 Most Recently Viewed Articles

Poland Stock Market Shows Positive Gains as WIG30 Rises 1.81%

Updated Category News Views 107

Poland Stock Market Performance Overview The Polish stock market exhibited strong performance recently, with stocks closing higher on the WIG30 index. The significant rise of 1.81% signifies robust growth, showcasing the resilience of the market amidst global tensions. This positive momentum can be attributed to key sectors, including Oil & Gas, Developers, and...

Continue Reading
Investors Urged to Take Action in PepGen Securities Case

Updated Category News Views 122

Investigation into PepGen Inc. Securities Claims Faruqi & Faruqi, LLP, recognized as a national securities law firm, has launched an investigation concerning potential claims on behalf of investors in PepGen Inc. (NASDAQ: PEPG). If you experienced losses while investing in PepGen, it’s crucial to understand your legal rights and options available to you. Reach Out for...

Continue Reading
Exploring the Future of Wellness in Travel Industry

Updated Category News Views 314

Key Discussions at the Global Wellness Summit Executives from leading wellness travel organizations such as Six Senses, Chenot, Lanserhof, Clinique La Prairie, and Kerzner are set to join influential investors, academics, and government tourism officials. Together, they will delve into the future of the $830 billion wellness tourism market, which is rapidly adapting to...

Continue Reading
China Cuts Rates to Stimulate Economic Growth Amid Global Changes

Updated Category News Views 175

China's Central Bank Steps Up to Support the Economy In a notable effort to invigorate its economy, China’s central bank has cut a key short-term interest rate and poured significant liquidity into the financial system. This proactive approach aims to encourage economic growth amidst the challenges posed by the global financial environment. Overview of the Recent Rate...

Continue Reading
Sobi's Q1 2025 Financial Insights and Future Expectations

Updated Category News Views 300

Sobi's Q1 2025 Financial Results Showcase Robust Performance Swedish Orphan Biovitrum AB (publ) (Sobi) has recently shared its financial outcomes for the first quarter of 2025, highlighting a steady progression in its overall portfolio. This report reveals a noteworthy 3% increase in total revenue, amounting to SEK 6,465 million, which remains consistent even at constant...

Continue Reading